Alizyme dropping renzapride

Alizyme (LSE:AZM) discontinued development of renzapride after data from a placebo-controlled Phase III trial to treat constipation-predominant irritable bowel syndrome in 1,798 patients showed limited efficacy. Although renzapride met the study's primary endpoint of a significant improvement in the duration of symptom relief vs. placebo, Alizyme said the mixed serotonin 5-HT4 receptor agonist/5-HT3 receptor antagonist showed "limited effects" on secondary endpoints including abdominal pain relief, bowel problem relief and relief of bloating. On the primary endpoint, 60% of renzapride patients reported improvement in overall symptoms vs. 55% of placebo patients. ...